http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Structure-Guided Generation of a Redox-Independent Blue Fluorescent Protein from mBFP
Seo, Pil-Won,Jo, Eun-Seo,You, Sung-Hwan,Cheong, Dae-Eun,Kim, Geun-Joong,Kim, Jeong-Sun Elsevier 2019 Journal of molecular biology Vol.431 No.17
<P><B>Abstract</B></P> <P>Fluorescent proteins, such as the green fluorescent protein, are used for detection of cellular components and events. However, green fluorescent protein and its derivatives have limited usage under anaerobic conditions and require a long maturation time. On the other hand, the NADPH-dependent blue fluorescent protein (BFP) without oxidative modification of residues is instantly functional in both aerobic and anaerobic systems. BFP proteins belong to a short-chain dehydrogenase/reductase (SDR) protein family, and their fluorescent property changes with reaction time in the presence of a substrate. With the aim of developing a better fluorescent reporter independent of redox state, we elucidated the crystal structure of a tetrameric mBFP from soil metagenomes with and without NADPH. Apart from the previously known regions, structure-guided mutational studies have identified several residues that contribute to the fluorescence of mBFP, including two aromatic residues (F97 and Y157) near the nicotinamide moiety of the bound NADPH. A single histidine mutation at Y157 (Y157H) has conferred more stabilized, time-independent fluorescence even in the presence of substrates. Furthermore, we discovered another SDR protein that can also emit blue fluorescence. These results open a new possibility for the development of BFP as a stable cellular reporter for widespread use, independent of subcellular environments.</P> <P><B>Highlights</B></P> <P> <UL> <LI> mBFP is an NADPH-dependent blue fluorescent protein. </LI> <LI> Its fluorescence changes by oxidizing or reducing putative substrates. </LI> <LI> Structure-guided mBFP derivative emits a constant fluorescence with substrates. </LI> <LI> mBFP can be used as a stable cellular reporter regardless of redox states. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
( Pil-won Seo ),( Ho-chang Ryu ),( Do-heon Gu ),( Hee-sae Park ),( Suk-youl Park ),( Jeong-sun Kim ) 한국미생물생명공학회(구 한국산업미생물학회) 2018 Journal of microbiology and biotechnology Vol.28 No.8
2-Keto-3-deoxy-6-phosphogluconate (KDPG) aldolase, which catalyzes aldol cleavage and condensation reactions, has two distinct substrate-binding sites. The substrate-binding mode at the catalytic site and Schiff-base formation have been well studied. However, structural information on the phosphate-binding loop (P-loop) is limited. Zymomonas mobilis KDPG aldolase is one of the aldolases with a wide substrate spectrum. Its structure in complex with the substrate-mimicking 3-phosphoglycerate (3PG) shows that the phosphate moiety of 3PG interacts with the P-loop and a nearby conserved serine residue. 3PG-binding to the P-loop replaces water molecules aligned from the P-loop to the catalytic site, as observed in the apostructure. The extra electron density near the P-loop and comparison with other aldolases suggest the diversity and flexibility of the serine-containing loop among KDPG aldolases. These structural data may help to understand the substrate-binding mode and the broad substrate specificity of the Zymomonas KDPG aldolase.
Seo, Dongwook,Lee, Si Un,Oh, Chang Wan,Kwon, O-Ki,Ban, Seung Pil,Kim, Tackeun,Byoun, Hyoung Soo,Kim, Young Deok,Lee, Yongjae,Won, Yu Deok,Bang, Jae Seung The Korean Neurosurgical Society 2019 Journal of Korean neurosurgical society Vol.62 No.6
Objective : To analyze the angiographic features and clinical course, including treatment outcomes and the natural course, of fusiform middle cerebral artery aneurysms (FMCAAs) according to their location, size, and configuration. Methods : We reviewed the literature on adult cases of FMCAAs published from 1980 to 2018; from 25 papers, 112 FMCAA cases, for which the location, size, and configuration could be identified, were included in this study. Additionally, 33 FMCAA cases in our hospital were included, from which 16 were assigned to the observation group. Thus, a total of 145 adult FMCAA cases were included. We classified the FMCAAs according to their location (l-type 1, beginning from prebifurcation; l-type 2, beginning from bifurcation; l-type 3, beginning from postbifurcation), size (small, <10 mm; large, ${\geq}10mm$; giant, ${\geq}25mm$), and configuration (c-type 1, classic dissecting aneurysm; c-type 2, segmental ectasia; c-type 3, dolichoectatic dissecting aneurysm). Results : The c-type 3 was more commonly diagnosed with ischemic symptoms (31.8%) than hemorrhage (13.6%), while 40.9% were found accidentally. In contrast, c-type 2 was more commonly diagnosed with hemorrhagic symptoms (14.9%) than ischemic symptoms (10.6%), and 72.3% were accidentally discovered. According to location, ischemic symptoms and hemorrhage were the most frequent symptoms in l-type 1 (28.6%) and l-type 3 (34.6%), respectively. Most of l-type 2 FMCAAs were found incidentally (68.4%). Based on the size of FMCAAs, only 11.1% of small aneurysms were found to be hemorrhagic, while 18.9% and 26.0% of large and giant aneurysms were hemorrhagic, respectively. Although four aneurysms of the 16 FMCAAs in the observation group increased in size and one aneurysm decreased in size during the observation period, no rupture was seen in any case and there were no significant predictors of aneurysm enlargement. Of 104 FMCAAs treated, 14 cases (13.5%) were aggravated than before surgery and all the aggravated cases were l-type 1. Conclusion : While ischemic symptoms occurred more frequently in l-type 1 and c-type 3, hemorrhagic rather than ischemic symptoms occurred more frequently in l-type 3 and c-type 2. In case of l-type 1 FMCAAs, more caution is required in determining the treatment due to the relatively high complication rate.
Pil Moon Kang,Won Ik Seo,Jae Il Chung 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.2
Purpose: We report our experience with modified 6+3 maintenance BCG therapy compared with a 6-week induction course over the past 10 years and its effects on recurrence and progression. Materials and Methods: Between January 2001 and June 2012, a total of 181 patients treated with NMIBC underwent TUR and intravesical BCG. BCG was administered over a 6-week course in 88 patients, and was administered for six weeks followed by three weekly instillations at 3, 6, 9, 12, 18, 24, and 36 months (modified 6+3 regimen) in 93 patients. The recurrence rate, time to recurrence, and progression rate were assessed and analyzed. Results: A total of 30 of 181 patients were ineligible. Seventy-three patients in the 6-week induction group and seventy-eight patients in maintenance group were eligible. Median follow-up was 37.4 months in the maintenance group and 32.9 months in the 6-week course group. The estimated overall recurrence rate and median recurrence-free survival were 21.8% (17/78) and 23.4 months (95% confidence interval [CI] 7-84) in the maintenance group and 35.6% (26/73) and 21.5 months (6-80) in the 6-week course group (log rank p=0.002), respectively. Estimated median times for progression-free survival were 44.0 months (95% CI 7-84) in the maintenance group and 25.7 months (14-41) in the 6-week course group (log rank p=0.0815). The overall rates of adverse effects were 27.9% (26/93) in the maintenance group and 25.0% (22/88) in the 6-week course group. Conclusions: Compared to the standard 6-week course, maintenance BCG immunotherapy was beneficial for preventing recurrence in patients with non-muscle-invasive bladder cancer.